Granada Perea

Summary

Affiliation: Hospital de la Santa Creu i Sant Pau
Country: Spain

Publications

  1. ncbi Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems
    G Perea
    Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain
    Ann Oncol 16:1508-13. 2005
  2. ncbi International and Italian prognostic indices in follicular lymphoma
    Granada Perea
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Haematologica 88:700-4. 2003
  3. ncbi Acute myeloid leukemia subgroups identified by pathway-restricted gene expression signatures
    Elena Serrano
    Laboratori d Hematologia, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Acta Haematol 116:77-89. 2006
  4. ncbi Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
    Mariano Monzo
    Hospital Clinic, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain
    Blood 107:4871-9. 2006
  5. ncbi High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma
    Antonio Salar
    Department of Clinical Hematology from Hospital del Mar, Hospital de la Santa Cruz y San Pablo, Hospital Germans Trias i Pujol, Hospital Clinic, Barcelona, Spain
    Haematologica 87:1028-35. 2002
  6. ncbi Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia
    Josep F Nomdedeu
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Hematol 84:368-75. 2005
  7. doi Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach
    Josep F Nomdedeu
    Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Hematol Oncol . 2016
  8. doi Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1
    Maria Rozman
    Hematopathology Unit, Pathology Department, and Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Ann Hematol 93:1695-703. 2014
  9. ncbi Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study
    Rodrigo Martino
    Servei d Hematologia Clinica, Hospital de la Santa Creu i Sant Pau, Av Sant Antoni M a Claret 167, 08025 Barcelona, Spain
    Haematologica 87:822-7. 2002
  10. ncbi Clonal heterogeneity assessed by flow cytometry in B-cell lymphomas arising from germinal centers
    Mar Bellido
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Am J Clin Pathol 117:864-70. 2002

Collaborators

Detail Information

Publications13

  1. ncbi Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems
    G Perea
    Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain
    Ann Oncol 16:1508-13. 2005
    ..Two new prognostic indexes have recently been proposed for FL [the Italian Lymphoma Intergroup (ILI) Index and the Follicular Lymphoma International Prognostic Index (FLIPI)]...
  2. ncbi International and Italian prognostic indices in follicular lymphoma
    Granada Perea
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Haematologica 88:700-4. 2003
    ..The Italian Lymphoma Intergroup (ILI) created a new prognostic index specific for FL. The aim of this study was to compare which of these two indices is more useful when applied to a large group of FL patients...
  3. ncbi Acute myeloid leukemia subgroups identified by pathway-restricted gene expression signatures
    Elena Serrano
    Laboratori d Hematologia, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Acta Haematol 116:77-89. 2006
    ..In accordance with previous results, Meis1 downregulation is a useful surrogate marker indicating a good prognosis in AML patients. Simple qPCR platforms may help to identify different biologic subgroups in AML...
  4. ncbi Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
    Mariano Monzo
    Hospital Clinic, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain
    Blood 107:4871-9. 2006
    ..4; P = .02) and MDR1 (RR = 2.1; P = .02) variant alleles, and WBC count (RR = 2.1; P = .02). These findings might be useful in selecting risk-adapted treatment strategies in intermediate-risk AML...
  5. ncbi High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma
    Antonio Salar
    Department of Clinical Hematology from Hospital del Mar, Hospital de la Santa Cruz y San Pablo, Hospital Germans Trias i Pujol, Hospital Clinic, Barcelona, Spain
    Haematologica 87:1028-35. 2002
    ..A salvage program including infusional high-dose ifosfamide plus etoposide (IFOVM) was evaluated in patients with refractory or relapsed aggressive non-Hodgkin's lymphoma...
  6. ncbi Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia
    Josep F Nomdedeu
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Hematol 84:368-75. 2005
    ..hMLH1 promoter was hypermethylated in five MSI+ cases. Overall survival analysis revealed no adverse effect of MSI positivity. These results suggest that MSI may be a common biologic finding in de novo AML...
  7. doi Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach
    Josep F Nomdedeu
    Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Hematol Oncol . 2016
    ..These results suggest that the AML profiler could be useful in multicentre trials to rapidly identify patients with AML with a good prognosis. Copyright © 2016 John Wiley & Sons, Ltd...
  8. doi Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1
    Maria Rozman
    Hematopathology Unit, Pathology Department, and Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Ann Hematol 93:1695-703. 2014
    ..599, 1.026-2.492; p = 0.038). In conclusion, MLD identifies a subgroup of patients with poorer outcome among patients with IR-AML and wild-type NPM1...
  9. ncbi Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study
    Rodrigo Martino
    Servei d Hematologia Clinica, Hospital de la Santa Creu i Sant Pau, Av Sant Antoni M a Claret 167, 08025 Barcelona, Spain
    Haematologica 87:822-7. 2002
    ..Anthracycline-based combination chemotherapy regimens are the standard therapy for patients with diffuse large B-cell lymphoma (DLBCL), but such regimens may be poorly tolerated in elderly patients...
  10. ncbi Clonal heterogeneity assessed by flow cytometry in B-cell lymphomas arising from germinal centers
    Mar Bellido
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Am J Clin Pathol 117:864-70. 2002
    ..The 3 flow cytometric patterns were observed, respectively, in de novo DLBCL and BL, transformation into BL, and transformation into DLBCL. Flow cytometric data can provide valuable information about the natural history of NHL...
  11. ncbi Low frequency of exon 3 PTPN11 mutations in adult de novo acute myeloid leukemia. Analysis of a consecutive series of 173 patients
    Josep Nomdedeu
    Haematologica 90:412-3. 2005
    ..Only three monocytic leukemias had point mutations (1.73%)...
  12. ncbi A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia
    Adriana Lasa
    Haematologica 91:1283-4. 2006
    ..c-KIT mutations were present in only two cases (6.6%) and were shown to be associated with an adverse outcome. The frequency of c-KIT mutations described here is much lower than in other reports...
  13. ncbi Microsatellite instability may involve the pentanucleotide repeat of the PIG3 promoter in bcr/abl acute lymphoblastic leukemia
    Josep F Nomdedeu
    Leuk Res 32:186-8. 2008